NPPA and infection: Prospective confirmatory studies are warranted for assessing the role that a therapeutic drug monitoring guided therapy of CAZ-AVI administered by CI may have in improving the outcome of infections caused by KPC-Kp with borderline susceptibility or even with theoretical CAZ-AVI in vitro resistance.